Holdings of Sanofi
· Original filing · Compare with another fund · Report an error
- Net assets
- -
- Positions
- 8 in 2 countries
- Top ten
- 100.0 % of the equity sleeve
- Filed on
- Mar 31, 2026
Portfolio shape
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Inhibrx Biosciences Inc | 1,157,926 | 77.8M $ | |
| 2 | Novavax Inc | 6,880,481 | 56M $ | |
| 3 | AnaptysBio Inc | 821,917 | 30.4M $ | |
| 4 | AGOMAB THERAPEUTICS SA | 2,783,096 | 29.2M $ | |
| 5 | MAPLIGHT THERAPEUTICS INC | 912,041 | 18.5M $ | |
| 6 | Immuneering Corp | 2,708,559 | 14.3M $ | |
| 7 | Eledon Pharmaceuticals Inc | 814,980 | 2.5M $ | |
| 8 | Q32 Bio Inc | 244,083 | 1.6M $ |
Sector breakdown
- Unattributed 100.0 %
Titelia assigns each company to a sector, one by one. The unassigned share stays visible, under "Unattributed".
Currency breakdown
- USD 100.0 %
Each line is counted in its quoted currency, as the fund declares it.
Country breakdown
- United States 87.3 %
- Belgium 12.7 %
Shares are computed on the fund's equities only.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | United States | 7 | 201.1M $ | 87.32 % |
| 2 | Belgium | 1 | 29.2M $ | 12.68 % |
Cite this page
Titelia. "Holdings of Sanofi". https://titelia.com/en/funds/US13F1121404